Prehospital randomised assessment of a mechanical compression device in cardiac arrest (PaRAMeDIC) trial protocol by Perkins, Gavin D. et al.
 University of Warwick institutional repository: http://go.warwick.ac.uk/wrap 
 
This paper is made available online in accordance with 
publisher policies. Please scroll down to view the document 
itself. Please refer to the repository record for this item and our 
policy information available from the repository home page for 
further information.  
To see the final version of this paper please visit the publisher’s website. 
Access to the published version may require a subscription. 
Author(s):  Gavin D Perkins , Malcolm Woollard , Matthew W Cooke , 
Charles Deakin , Jessica Horton , Ranjit Lall , Sarah E Lamb , Chris 
McCabe , Tom Quinn , Anne Slowther  and Simon Gates 
Article Title: Prehospital Randomised Assessment of a Mechanical 
Compression Device In Cardiac Arrest (PaRAMeDIC) Trial Protocol 
Year of publication: 2010 
Link to published article: http://dx.doi.org/10.1186/1757-7241-18-58 
Publisher statement:  None 
 
 
 
This Provisional PDF corresponds to the article as it appeared upon acceptance. Fully formatted
PDF and full text (HTML) versions will be made available soon.
Prehospital Randomised Assessment of a Mechanical Compression Device In
Cardiac Arrest (PaRAMeDIC) Trial Protocol
Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine 2010,
18:58 doi:10.1186/1757-7241-18-58
Gavin D Perkins (g.d.perkins@warwick.ac.uk)
Malcolm Woollard (aa38378@coventry.ac.uk)
Matthew W Cooke (m.cooke@warwick.ac.uk)
Charles Deakin (charlesdeakin@doctors.org.uk)
Jessica Horton (jessica.horton@warwick.ac.uk)
Ranjit Lall (r.lall@warwick.ac.uk)
Sarah E Lamb (s.lamb@warwick.ac.uk)
Chris McCabe (c.mccabe@leeds.ac.uk)
Tom Quinn (t.quinn@surrey.ac.uk)
Anne Slowther (a-m.slowther@warwick.ac.uk)
Simon Gates (s.gates@warwick.ac.uk)
ISSN 1757-7241
Article type Study protocol
Submission date 17 September 2010
Acceptance date 5 November 2010
Publication date 5 November 2010
Article URL http://www.sjtrem.com/content/18/1/58
This peer-reviewed article was published immediately upon acceptance. It can be downloaded,
printed and distributed freely for any purposes (see copyright notice below).
Articles in SJTREM are listed in PubMed and archived at PubMed Central.
For information about publishing your research in SJTREM or any BioMed Central journal, go to
http://www.sjtrem.com/info/instructions/
For information about other BioMed Central publications go to
Scandinavian Journal of
Trauma, Resuscitation and
Emergency Medicine
© 2010 Perkins et al. , licensee BioMed Central Ltd.
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
http://www.biomedcentral.com/
Scandinavian Journal of
Trauma, Resuscitation and
Emergency Medicine
© 2010 Perkins et al. , licensee BioMed Central Ltd.
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1(14) 
Prehospital Randomised Assessment of a Mechanical Compression 
Device In Cardiac Arrest (PaRAMeDIC) Trial Protocol 
 
Gavin D Perkins, Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, 
Gibbet Hill Road, Coventry CV4 7AL, United Kingdom, G.D.Perkins@warwick.ac.uk (Corresponding 
Author) 
 
Malcolm Woollard, Pre-hospital, Emergency and Cardiovascular Care Applied Research Group, 
Coventry University, Priory Street, Coventry, CV1 5FB, United Kingdom,  aa3738@coventry.ac.uk  
 
Matthew W Cooke, Warwick Medical School, University of Warwick, Coventry, CV4 7AL, United 
Kingdom,  M.W.Cooke@warwick.ac.uk 
 
Charles Deakin, Dept of Anaesthetics, Southampton General Hospital, Tremona Road, 
Southampton, SO16 6YD, United Kingdom, charlesdeakin@doctors.org.uk  
 
Jessica Horton, Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Gibbet 
Hill Road, Coventry CV4 7AL, United Kingdom,  Jessica.Horton@warwick.ac.uk  
 
Ranjit Lall, Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Gibbet Hill 
Road, Coventry CV4 7AL, United Kingdom, R.Lall@warwick.ac.uk  
 
Sarah E Lamb, Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Gibbet 
Hill Road, Coventry CV4 7AL, United Kingdom, S.lamb@warwick.ac.uk  
 
Chris McCabe, Academic Unit of Health Economics, Leeds Institute of Health Sciences 
Charles Thackrah Building, University of Leeds, 101 Clarendon Road, Leeds, LS2 9LJ, United 
Kingdom, C.McCabe@leeds.ac.uk  
Tom Quinn, 23DK04, Duke of Kent Building, Division of Health and Social Care, Faculty of Health and 
Medical Sciences, University of Surrey, Guildford, United Kingdom,  GU2 7XH, t.quinn@surrey.ac.uk   
Anne Slowther, University of Warwick, Medical Teaching Building, University of Warwick, Coventry, 
CV4 7AL, United Kingdom, a-m.slowther@warwick.ac.uk 
Simon Gates, Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Gibbet 
Hill Road, Coventry CV4 7AL, United Kingdom, S.Gates@warwick.ac.uk  
2(14) 
ABSTRACT 
Background: Survival after out-of-hospital cardiac arrest is closely linked to the quality of CPR, but in 
real life, resuscitation during prehospital care and ambulance transport is often suboptimal.  
Mechanical chest compression devices deliver consistent chest compressions, are not prone to 
fatigue and could potentially overcome some of the limitations of manual chest compression.  
However, there is no high-quality evidence that they improve clinical outcomes, or that they are 
cost effective. The Prehospital Randomised Assessment of a Mechanical Compression Device In 
Cardiac Arrest (PARAMEDIC) trial is a pragmatic cluster randomised study of the LUCAS-2 device in 
adult patients with non-traumatic out-of-hospital cardiac arrest. 
Methods/design: The primary objective of this trial is to evaluate the effect of chest compression 
using LUCAS-2 on mortality at 30 days post out-of-hospital cardiac arrest, compared with manual 
chest compression. Secondary objectives of the study are to evaluate the effects of LUCAS-2 on 
survival to 12 months, cognitive and quality of life outcomes and cost-effectiveness.  Methods:  
Ambulance service vehicles will be randomised to either manual compression (control) or LUCAS 
arms.  Adult patients in out-of-hospital cardiac arrest, attended by a trial vehicle will be eligible for 
inclusion.  Patients with traumatic cardiac arrest or who are pregnant will be excluded.  The trial will 
recruit approximately 4000 patients from England, Wales and Scotland. A waiver of initial consent 
has been approved by the Research Ethics Committees. Consent will be sought from survivors for 
participation in the follow-up phase.   
Conclusion: The trial will assess the clinical and cost effectiveness of the LUCAS-2 mechanical chest 
compression device. Trial Registration: The trial is registered on the International Standard 
Randomised Controlled Trial Number Registry (ISRCTN08233942).   
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BACKGROUND  
Sudden cardiac death is a major cause of death and morbidity in the Western world. In 
Europe, approximately 700,000 people sustain a cardiac arrest in the community each year[1-2]. 
Resuscitation is attempted in about 45% of cases of which approximately 20% achieve a return of 
spontaneous circulation by the time of arrival at hospital and about 5% survive to hospital 
discharge[3-4]. Good quality cardiopulmonary resuscitation (CPR) has a significant impact on 
the likelihood of survival[5-7], yet it is difficult to perform in the prehospital environment due 
to the multiple tasks required upon arrival at a cardiac arrest. In addition, rescuer fatigue can 
reduce chest compression quality as early as 1 minute after commencing chest compressions[8]. 
The LUCAS-2 is a mechanical device that delivers sternal compressions at a constant rate of 100 per 
minute, to a fixed depth of 4cm to 5cm, using a piston with a suction cup attached that returns the 
chest to its normal expanded position. The rate and depth comply with International scientific 
guidelines on CPR[9]. It is easy to apply, stable in use, relatively light in weight (7.8 kg), and well 
adapted to use during patient movement on a stretcher and during ambulance transportation. The 
device is CE marked and has been on the market since 2002 in Europe.  The device was originally 
gas-powered, a battery powered version (LUCAS-2) was introduced in 2009. Detailed descriptions of 
the device and experimental data from animal studies reporting increased cardiac output and cortical 
cerebral flow compared to manual standardised CPR have been published[10]. However there is a 
lack of robust evidence from human trials for the clinical and cost effectiveness of the device [11-
12].  
 
The Prehospital Randomised Assessment of a Mechanical Compression Device In Cardiac Arrest 
(PARAMEDIC) trial is a cluster randomised pragmatic trial of the clinical and cost effectiveness of the 
LUCAS-2 device versus manual chest compression, for adult patients in whom resuscitation is 
attempted following non-traumatic out-of-hospital cardiac arrest. 
METHODS/DESIGN 
Trial Approvals and Conduct 
The trial is approved by the Coventry Research Ethics committee (for England and Wales) and 
Scotland A Research Ethics Committee.  The trial is registered on the International Standard 
Randomised Controlled Trial Registry (ISRCTN08233942). It will be carried out in accordance with 
the Medical Research Council (MRC) Good Clinical Practice Guidelines[13], applicable UK legislation 
and the Standard Operating Procedures of the Warwick Clinical Trials Unit.  The sponsor 
organisation for the trial is the University of Warwick.  The trial is funded by the National Institute 
for Health Research (NIHR) Health Technology Assessment (HTA) Programme[14] and is a 
collaboration between the Universities of Warwick, Coventry, Leeds, Southampton and Surrey and 
the West Midlands, Scottish and Welsh NHS Ambulance Services.  Further details can be found on 
the trial website[15]. 
The contribution of the manufacturers (JOLIFE AB) and distributors (Physio-Control UK) of the 
LUCAS-2 device will be limited to supply and servicing of LUCAS-2 devices, and training of study co-
ordinating centre personnel. They will have no role in the design, conduct, analysis or reporting of 
the trial.   
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Outcome Measures 
The primary outcome for the trial is survival to 30 days post cardiac arrest.  Secondary outcomes are: 
survival of event (sustained return of spontaneous circulation (ROSC) to arrival at hospital ); survival to 
hospital discharge and to 12 months; health related quality of life at 3 and 12 months (measured by 
SF12 and EQ-5D); neurologically intact survival to 3 months (survival with Cerebral Performance 
Category (CPC) score 1 or 2); cognition at 12 months (Mini Mental State Examination (MMSE); 
anxiety and depression at 12 months (Hospital Anxiety and Depression Scale (HADS)); post 
traumatic stress at 12 months (PTSD civilian checklist (PCL-C)); hospital length of stay; intensive care 
length of stay. 
Eligibility Criteria 
Vehicles that are in service at participating ambulance stations and may attend cardiac arrests 
will be included in the trial, and will randomised before recruitment starts to either the LUCAS or 
manual chest compression (control) arms.  To maximise the efficiency of the trial, recruitment 
will be predominantly concentrated in urban areas. 
Individual patients will be eligible if: 
1. they are in cardiac arrest in the out-of-hospital environment on arrival of a trial vehicle; 
2. the first ambulance resource to arrive is a trial vehicle 
3. a resuscitation attempt is initiated by the attending paramedic, according to UK 
national guidelines;  
4. the patient is known or believed to be aged 18 years or over. 
 
Exclusion criteria will be: 
1. traumatic cardiac arrest 
2. known or clinically apparent pregnancy. 
Treatment allocation of each individual participant will be determined by the first trial vehicle to 
arrive on scene. If this is a LUCAS trial vehicle, the patient will be included in the LUCAS arm, and 
if it is a control trial vehicle, the patient will be in the control arm. If a non-trial ambulance or rapid 
response vehicle arrives first and resuscitation is started, the patient will be excluded.  
Power and Sample Size 
There are no national data on survival to 30 days post cardiac arrest.  However, it is likely to be 
very similar to survival to hospital discharge, as most mortality will occur in the period 
immediately following a cardiac arrest.  In a systematic review[1], the average survival to 
hospital discharge in 8 studies conducted in the UK was 8.1%. National audit data for England 
(2004-2006) indicate that the proportion of patients with ROSC at hospital admission is 14 to 
16%[4].  Estimates of mortality in hospital vary from 50% to 70%, hence the incidence of 
survival to hospital discharge is expected to be between 4.5% and 8%[16].  A conservative 
estimate of survival to 30 days is therefore 5%. 
 
No data currently exist from which a relevant intracluster correlation coefficient (ICC) can be 
calculated, and we have therefore assumed a conservative value of 0.01. The value of the ICC will 
be monitored at interim analyses by the Data Monitoring Committee (DMC), who will make 
recommendations for adjustments to the required sample size. 
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Sample Size Required 
We aim to detect, with 80% power, an increase in the incidence of survival to 30 days from 5% in 
the control arm to 7.5% in the LUCAS arm (a risk ratio of 1.5). The number of LUCAS clusters 
(vehicles) is limited by the number of devices available, but because control clusters (vehicles) 
do not require any specific equipment, we can include more control clusters than LUCAS clusters 
in the trial (see figure 1).  Detection of the specified difference with a randomisation ratio of 1:2 
and a cluster size of 15 requires 82 LUCAS and 163 control clusters (3675 participants in total).  
The primary outcome will be determined for close to 100% of trial participants, so there is no 
adjustment for losses of individual patients.  
Consent 
Prospective consent from research participants prior to enrolment is impossible in this trial; the 
occurrence of an out-of-hospital cardiac arrest is unpredictable, and a victim becomes 
unconscious within seconds.  Treatment (in the form of CPR) must be started immediately in an 
attempt to save the person’s life.  It is therefore not practical to consult a carer or independent 
clinician without causing the potential participant harm as a result of delaying treatment.  
Conducting research in emergency situations where a patient lacks capacity is regulated by the 
Mental Capacity Act (2005) in England and Wales and the Adults with Incapacity Act (2000) in 
Scotland.  The relevant ethics committees have determined that the research methods are 
compliant with the requirements of this legislation. 
Consent for follow-up will be sought from all participants who survive to hospital discharge.  If a 
participant lacks capacity to give informed consent we will seek the views of a personal 
consultee in order to establish the patient’s wishes.   
Protection against Bias 
Cluster design 
Selection bias is a major potential problem in cluster randomised trials: patients with different 
characteristics may be recruited to the two trial arms[17].  Further bias can arise where a large 
proportion of eligible patients are not included in the trial, as the probability of inclusion may be 
related to the intervention.  In this trial we will identify eligible patients from routinely collected 
ambulance service data, which will allow us to identify and include close to 100% of the eligible 
patients, thus avoiding selection bias. 
 
Threshold for resuscitation 
Paramedics need to make a rapid decision as to whether to resuscitate someone in cardiac arrest 
upon arrival at the scene.  It is possible that application of the Recognition of Life Extinct (ROLE) 
criteria[18] will differ between the trial arms. If paramedics believe strongly that LUCAS-2 is 
effective, some of them may attempt to resuscitate patients in the LUCAS arm who have no chance 
of survival, and for whom a resuscitation attempt would not normally be considered.  This would 
result in a group of patients with very low probability of survival being recruited to the LUCAS arm 
but not the control arm, potentially masking any beneficial effect of LUCAS-2.   
We will monitor the accumulating trial data for evidence of a between-group difference in 
threshold as follows: (1) proportion of arrests where resuscitation attempted versus cardiac arrests 
attended  (2) patient age profile (3) proportion receiving bystander CPR (4) time from collapse to 
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trial vehicle arrival and (5) proportion of patients in asystole. If evidence of bias is detected 
corrective action will be taken. 
Compliance 
Compliance (whether LUCAS-2 was used for all eligible patients in the LUCAS-2 arm and none in the 
control arm) will be monitored by review of ECG recordings taken during resuscitation. Recorded 
compression waveforms will be analysed to determine whether LUCAS-2 was used and to confirm 
the presenting rhythm and duration of resuscitation.    
Learning effects 
Because LUCAS-2 will be new to paramedics in the areas where the trial is conducted, there is a 
possibility that there will be a learning effect, and its apparent effectiveness may increase 
through time as personnel become more familiar with its use.  We will therefore allow a “run-in” 
period before the start of recruitment to the trial at each station. Participating vehicles will be 
randomised at the start of this period, LUCAS-2 will be used in the LUCAS arm, and trial data will 
be collected but will not be included in the main trial analysis.  
Crew preferences 
With randomisation by vehicle, a potential source of bias is that paramedics who are motivated 
to use LUCAS-2 will select LUCAS vehicles, whilst those who dislike the device may avoid it.  In 
order to check for this possibility, we will review records of crews members present at each 
cardiac arrest to check individuals who consistently appear in one arm. If swapping between 
LUCAS and control trial vehicles is found to occur, the staff involved will be given extra training in the 
trial procedures. 
Blinding 
Because of the nature of the interventions, paramedics cannot be blinded, and will be aware of 
treatment allocations. Control room personnel will be blinded to the allocation of the 
ambulance service vehicles, to ensure that there is no bias in whether a LUCAS or control trial 
vehicle is sent to an incident that is likely to be a cardiac arrest.  Patients themselves will be 
unaware of their treatment allocation at the time of the intervention, though they may 
subsequently be unblinded by relatives or friends who are aware that LUCAS-2 was used.  To 
ensure blinding of outcome assessment as far as possible, research nurses assessing patients at 
follow-up visits will be blinded to the allocated treatment group.  
Trial Intervention / Treatments 
LUCAS arm 
The trial will use the LUCAS-2 device, (JOLIFE AB, Ideon Science Park, Scheelevägen 17, SE-223 70 
Lund, Sweden).  
The LUCAS arm will receive resuscitation according to the Resuscitation Council (UK)[19] and Joint 
Royal College Ambulance Liaison Committee (JRCALC) advanced life support guidelines[20] with 
the exception that the LUCAS-2 device will be deployed to replace manual chest compressions (see 
figures 2 and 3). All standard advanced life support interventions will be provided including drug 
administration, defibrillation and advanced airway management as required. 
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On arrival, two minutes of LUCAS-2 CPR (5 cycles of 30:2) will be administered before a countershock 
if the patient is in ventricular fibrillation (VF) or pulseless ventricular tachycardia (VT). Operational 
experience shows that LUCAS-2 can be positioned and activated within 20 to 30 seconds of 
arrival at the patient. Prior to intubation, compressions will be provided using the 30 
compressions to 2 ventilation mode.  If the patient is intubated, asynchronous compressions and 
ventilations will be provided, with a ventilation rate of 10 per minute.  A bag-valve device will be 
used to manually provide ventilations.    
Defibrillation will be performed using the following sequence: stop LUCAS-2 device, analyse heart 
rhythm; if shock indicated, restart LUCAS-2, charge, deliver shock, continue CPR for 2 minutes. This 
will minimize deleterious pre and post shock pauses in compressions. The LUCAS-2 device will 
be used in place of standard chest compressions as long as continued resuscitation is indicated, 
including outside the ambulance and during transport to hospital. The trial intervention will 
cease after care is handed over to the medical team at hospital. 
If a patient in the LUCAS arm arrives at hospital with the LUCAS-2 device running, the device should 
be removed and resuscitation should continue with manual compressions.  Hospitals will be given 
information about the trial prior to the start of recruitment. 
Manual chest compression arm 
The control arm will receive resuscitation according to the Resuscitation Council (UK) and 
JRCALC Advanced Life Support Guidelines.  
Guidelines change in 2010 
The International Liaison Committee for Resuscitation and European Resuscitation Council (UK) will 
publish new resuscitation guidelines on 18
th
 October 2010.  There is likely to be a delay before 
these are incorporated into clinical practice.  The LUCAS-2 and manual chest compression 
protocols will be updated to coincide with the adoption of the new guidelines in the respective 
ambulance services.  A subgroup analysis will be undertaken to compare treatment effects of 
LUCAS-2 before and after introduction of the new guidelines. 
Data Collection 
Data up to admission to hospital will be extracted from routinely collected ambulance service data, 
and will be supplied to the trial database in anonymised form. Local Register Offices will be 
contacted by ambulance services after each individual’s cardiac arrest, to verify whether the 
participant is alive and to ensure that communications about participation in the follow-up are not 
sent to deceased individuals. If patients have died, the date and location of death will be recorded.  
Trial participants will be flagged on the NHS Central Register so that later deaths will be notified 
to the trial.  
Follow-up 
Where consent is given, surviving participants will be followed up approximately 3 months after 
their cardiac arrest, by a home visit from a study research nurse or paramedic. At this visit the 
quality of life measures will be completed, details of ICU and hospital discharge dates will be 
collected, and an assessment of CPC score made. 
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The second follow-up visit at 12 months will include quality of life, anxiety and depression (HADS), 
post-traumatic stress (PCL-C) and Mini-Mental State Examination (MMSE).  Health service and 
social care resource use will be recorded by participants at the 3 month and 12 month follow-up. 
Serious Adverse Events (SAEs) and Serious Adverse Device Effects (SADEs) 
SAEs and SADEs will be reported to the trial co-ordinating centre if they fulfil the criteria for 
seriousness, they are potentially related to trial participation, and they are unexpected i.e. the 
event is not an expected occurrence for patients who have had a cardiac arrest.  
Statistical Analysis  
All analyses will be by intention to treat, and all estimates will be adjusted to account for the 
cluster randomised design. Dichotomous outcomes (survival to 30 days, hospital discharge, 3 
months and 12 months, and neurologically intact survival) will be presented as risk ratios and 95% 
confidence intervals.  Survival will also be analysed as a time to event outcome, using survival 
analysis, with adjustment for clustering and important covariates.  Results will be presented using 
hazard ratios and their 95% confidence intervals. Other time to event outcomes (duration of 
hospital and ICU stay) will be analysed in the same way.  Continuous outcomes (quality of life, 
anxiety and depression, cognition and post traumatic stress) will be analysed by multi-level linear 
regression, with adjustments for important covariates.  The results will be presented as the 
difference in means between the groups and its 95% confidence interval.  CPC score will be 
analysed by multi-level ordinal logistic regression[21] and the results will be presented using odds 
ratios   and their 95% confidence intervals.  Reporting of analyses will follow CONSORT guidelines 
for the reporting of cluster randomised trials[22].  A detailed analysis plan will be drawn up by the 
study statisticians and approved by the DMC. 
 
Four pre-specified subgroup analyses will be conducted to conform with Utstein 
recommendations: witnessed cardiac arrest versus not witnessed; bystander CPR versus no 
bystander CPR; type of initial rhythm (VF/VT; PEA; asystole); presumed cardiac aetiology of cardiac 
arrest.  Subgroup analyses will use statistical tests of interaction [23].  In addition, we will model 
the effects of age and the time interval from the 999 call to arrival of the trial vehicle on the effects 
of the LUCAS-2 intervention, using logistic regression analyses.  
 
Interim analyses will be conducted at least once per year during recruitment and supplied 
confidentially to the DMC, who will consider the results and make recommendations to the Trial 
Steering Committee (TSC) about continuation of recruitment or any modification to the trial that 
may be necessary. 
 
Economic analysis 
An economic evaluation will be conducted alongside the trial, consisting of a within-trial cost 
effectiveness analysis, comparing the observed costs and outcomes of the intervention and 
control groups during the trial period, and analysis of the long-term incremental cost effectiveness of 
LUCAS-2, by constructing a decision analytic cost effectiveness model with a lifetime horizon.  
For the within trial economic evaluation the interventions (LUCAS-2 vs. manual compression) will be 
compared in terms of Quality Adjusted Life Years (QALYs). The utility weights for calculating the 
QALYs will be derived from the EQ-5D and SF-12 [24] via the SF-6D algorithm[25]. The outcomes 
will be reported as the expected incremental cost effectiveness of LUCAS-2- compared to usual care. 
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CONCLUSION 
 
There remains an urgent need to improve outcomes from cardiac arrest.  The quality of CPR is 
known to significantly influence outcomes from cardiac arrest but despite this, in real life it is often 
performed suboptimally. Mechanical chest compression devices may overcome some of the 
limitations of manual CPR, yet there is a paucity of high quality clinical evidence to support their 
use. The PARAMEDIC trial is a large, multi-centre, pragmatic trial aiming to evaluate the clinical and 
cost effectiveness of the LUCAS-2 mechanical chest compression device in out-of-hospital cardiac 
arrest. 
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LIST OF ABBREVIATIONS 
 
CONSORT Consolidated Standards of Reporting Trials. CPR Cardiopulmonary resuscitation. DMC 
Data monitoring committee. EQ-5D EuroQol 5 Dimensions. HADS Hospital Anxiety and Depression 
Scale. JRCALC  Joint Royal College Ambulance Liaison Committee. LUCAS-2 Lund University 
Cardiopulmonary Assistance System. MMSE Mini Mental Health State Exam. OHCA Out-of-hospital 
cardiac arrest. PEA Pulseless electrical activity. QALYs Quality Adjusted Life Years. ROSC Return of 
spontaneous circulation. ROLE Recognition of life extinction. SAE Serious adverse event. SF-12 Short 
form-12. TSC Trial Steering Committee. VF Ventricular Fibrillation. VT Ventricular Tachycardia. 
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Figure 1: Flow chart for PARAMEDIC Trial 
Figure 2: Treatment algorithm for control arm 
Figure 3: Treatment algorithm for LUCAS arm 
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During CPR:
• Correct reversible causes
• Check electrode position and
contact
• Attempt / verify:
IV access
airway and oxygen
• Give uninterrupted
compressions when airway secure
• Give adrenaline every 3-5 min
• Consider: amiodarone, atropine,
magnesium
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During CPR:
• Correct reversible causes
• Check electrode position and
contact
• Attempt / verify:
IV access
airway and oxygen
• Give uninterrupted
compressions when airway secure
• Give adrenaline every 3-5 min
• Consider: amiodarone, atropine,
magnesium
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Figure 3
